Recursion Pharmaceuticals, Inc.
General ticker "RXRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.4B (TTM average)
Recursion Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 16.1%.
Estimated limits based on current volatility of 2.9%: low 4.48$, high 4.75$
Factors to consider:
- Total employees count: 800 (+60.0%) as of 2024
- Top business risk factors: Limited operating history and capital needs, Acquisition/divestiture risks, Cybersecurity threats, Expansion risks, Currency fluctuations
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.00$, 9.39$]
- 2025-12-31 to 2026-12-31 estimated range: [3.47$, 8.27$]
Financial Metrics affecting the RXRX estimates:
- Negative: with PPE of -4.1 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -19.28 <= 0.33
- Positive: Investing cash flow per share per price, % of 13.96 > -0.66
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of 71.43 > 63.39
Short-term RXRX quotes
Long-term RXRX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $39.84MM | $44.58MM | $58.84MM |
| Operating Expenses | $285.57MM | $394.63MM | $537.84MM |
| Operating Income | $-245.73MM | $-350.06MM | $-479.00MM |
| Non-Operating Income | $6.25MM | $17.93MM | $14.22MM |
| R&D Expense | $155.70MM | $241.23MM | $314.42MM |
| Income(Loss) | $-239.48MM | $-332.13MM | $-464.79MM |
| Taxes | $0.00MM | $-4.06MM | $-1.13MM |
| Profit(Loss)* | $-239.48MM | $-328.07MM | $-463.66MM |
| Stockholders Equity | $485.81MM | $463.44MM | $1,034.78MM |
| Assets | $701.29MM | $653.70MM | $1,448.60MM |
| Operating Cash Flow | $-83.52MM | $-287.78MM | $-359.17MM |
| Capital expenditure | $37.36MM | $11.96MM | $13.70MM |
| Investing Cash Flow | $193.25MM | $-10.23MM | $260.06MM |
| Financing Cash Flow | $154.34MM | $140.13MM | $304.12MM |
| Earnings Per Share** | $-1.36 | $-1.58 | $-1.69 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.